Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**NanoBio Protect** is an over-the-counter intranasal antiseptic product developed by **BlueWillow Biologics** for reduction of the risk of respiratory infection through topical nasal decontamination. The product is a **0.13% benzalkonium chloride** antiseptic formulated in a patented **oil-in-water nanodroplet** delivery system, with positively charged droplets reported to localize to negatively charged microorganisms on the skin inside and around the nose. Its mechanism is topical membrane disruption of susceptible bacteria and other microbes by benzalkonium chloride, producing rapid germicidal activity rather than a pathogen-specific receptor-mediated pharmacology. It is described as alcohol-free, fragrance-free, moisturizing, and intended for repeated application with a cotton swab every 4 to 8 hours, with claimed protection lasting up to 8 hours.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NanoBio Protect.